MedTrace Logo

Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain

NCT01316744 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2011-05-13

No results posted yet for this study

Summary

RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given together with the best pain management in treating neuropathic pain in patients with cancer.

PURPOSE: This randomized phase III trial is studying ketamine hydrochloride given together with the best pain management to see how well it works compared with giving a placebo together with the best pain management in treating cancer patients with neuropathic pain.

Conditions

Interventions

DRUG

ketamine hydrochloride

OTHER

pharmacogenomic studies

OTHER

questionnaire administration

PROCEDURE

assessment of therapy complications

PROCEDURE

quality-of-life assessment

Sponsors & Collaborators

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Marie T. Fallon · Edinburgh Cancer Centre at Western General Hospital

  • Barry J.A. Laird, MD · Edinburgh Cancer Centre at Western General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316744 on ClinicalTrials.gov